drugset / Trial / NCT06373146
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.
Timeline
- Start
- 2024-04-24
- Primary completion
- 2025-12-15
- Completion
- 2026-04-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mibavademab | Monoclonal antibody | — | Subcutaneous |
| Subject | Tirzepatide | Peptide | — | Subcutaneous |